You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said it continues to see the global tuberculosis market expanding, and it is investing in both commercial resources and R&D.
As part of the new sales process the firm launched a return-on-investment tool that adapts data from existing customers to predict potential outcomes.
The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.
The firm placed 137 commercially contracted instruments in the quarter and 304 in the full year 2019.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.
Test volumes, revenues per test and costs per test improved during the quarter, the company said.
The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.